UBS O'Connor’s Atara Biotherapeutics ATRA Stock Holding History

UBS O'Connor’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-934	Closed	-$734K	–	425
2015 Q3	$734K	Buy	+934	New	+$1.14M	0.01%	447

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS O'Connor's ATRA Position: Q4 2015 in Review

UBS O'Connor sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 934 shares — an estimated $734K sold.

UBS O'Connor first reported a position in ATRA in Q3 2015 and held it in 1 quarter. The position peaked at $734K in Q3 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

UBS O'Connor reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
UBS O'Connor sold 934 Atara Biotherapeutics shares in Q4 2015, an estimated $734K.
UBS O'Connor first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 1 quarter.
UBS O'Connor's Atara Biotherapeutics position peaked at $734K in Q3 2015.
85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on UBS O'Connor's 13F filing for Q4 2015, filed 10 Feb 2016.